In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

The post Eli Lilly secures weight loss drug approval in China: How do rivals stack up? appeared first on Invezz ...

The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Novo Nordisk announced in June that its weight-loss drug Wegovy received similar approval in China. Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from ...

China’s National Medical Products Administration approved Lilly’s shot for long-term weight management on Friday ... regulator initially cleared the drug for diabetes. The shares gained ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.